Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
03/11/19
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
- Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer – - Seres to receive $20 million and financial support for research activities – - Company to further discuss collaboration during webcast Cowen healthcare conference presentation scheduled for 11:20 a.m. ET today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2019-- Seres Therapeutics, I... 
03/06/19
Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
- Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis - - Initiated SER-401 Phase 1b study in metastatic melanoma - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported fourth quarter and full year 2018 financial results and provided an operational update. “This has been a highly eventful period where... 
03/05/19
Seres Therapeutics to Present at Three Upcoming March Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences: Chardan’s Inaugural Microbiome Summit: a corporate overview will be presented on Thursday, March 7th at 8:10 a.m. ET in New York, NY. Cowen and Company 39th Annual Health Care Conference: a corporate overview will be ... 
EventsMore
Download DocumentationCorporate Presentation

DateTitleRemind
Me
Prior to
Event
03/19/19 11:30 a.m. ET
Oppenheimer 29th Annual Healthcare Conference
  
Stock Quote
NASDAQ:MCRB
$6.65
 + 0.08 (1.22%)
03/19/19 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.